Vtv Therapeutics Stock Price, News & Analysis

vTv Therapeutics (Nasdaq: VTVT), a late-stage biopharmaceutical company developing cadisegliatin for type 1 diabetes treatment, has announced its participation in two major investor conferences in September 2025.

The company will attend the H.C. Wainwright 27th Annual Global Investment Conference on September 9, participating in one-on-one investor meetings. On the same day, management will also present at the Morgan Stanley 23rd Annual Global Healthcare Conference, featuring a fireside chat from 2:35 PM to 3:10 PM EST, along with individual investor meetings.

vTv Therapeutics (Nasdaq: VTVT) has secured an $80 million private placement financing from leading healthcare institutional investors and the T1D Fund. The funding will support the ongoing CATT1 Phase 3 trial of cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment.

The PIPE financing includes the sale of 682,018 shares of Class A Common Stock and pre-funded warrants for 4,561,714 shares, with accompanying warrants to purchase 5,243,732 shares. The unit price is set at $15.265 for common stock and $15.255 for pre-funded warrants, with accompanying warrants having an exercise price of $22.71 per share.

The company expects topline data from the CATT1 Phase 3 trial in the second half of 2026. The trial aims to evaluate cadisegliatin's potential in reducing hypoglycemic events and improving glycemic control in T1D patients.

vTv Therapeutics (Nasdaq: VTVT) reported Q2 2025 financial results and key developments in its cadisegliatin program for type 1 diabetes treatment. The company announced the first patient randomization in its Phase 3 CATT1 trial, with topline data expected in H2 2026. Financial results showed a net loss of $6.0 million ($0.92 per share) compared to $5.2 million ($0.81 per share) in Q2 2024.

The company's cash position stood at $25.9 million as of June 30, 2025, down from $36.7 million at year-end 2024. R&D expenses increased to $4.1 million from $3.4 million year-over-year, while G&A expenses slightly decreased to $3.6 million. Notable developments include strengthening intellectual property with a new patent allowance through 2041 and the appointment of Michael Tung as CFO.

vTv Therapeutics (Nasdaq: VTVT) has received a Notice of Allowance from the USPTO for a patent application covering crystalline forms of salts and co-crystals of cadisegliatin, their lead drug candidate. The patent, which extends through 2041, strengthens the intellectual property protection for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D) treatment.

The patent allowance represents a significant milestone in protecting vTv's innovative lead asset, reinforcing their commitment to developing novel therapeutic solutions.

vTv Therapeutics (Nasdaq: VTVT) has announced the randomization of its first participant in the CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral treatment for Type 1 Diabetes (T1D). The trial will evaluate cadisegliatin as an adjunctive treatment to insulin in adults with T1D.

The study will enroll approximately 150 participants across 25 U.S. sites, testing two dose regimens (800 mg once or twice daily) against placebo. The drug, which has received FDA Breakthrough Therapy designation, has shown good tolerability in over 500 subjects. The trial's primary endpoint focuses on hypoglycemic events, with topline results expected in second half of 2026.

vTv Therapeutics (VTVT) announced its participation in the virtual H.C. Wainwright 'HCW@Home' Series on June 12, 2025. The company, which focuses on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment, will participate in a fireside chat at 10:00 AM ET. Key company executives including Paul Sekhri (Chairman, President & CEO), Thomas Strack (CMO), Carmen Valcarce (CSO), and Michael Tung (CFO) will engage in the discussion moderated by Emily Bodnar from H.C. Wainwright. The event will be accessible via webcast on the company's website.

vTv Therapeutics (VTVT) has appointed Michael Tung, M.D., MBA as Executive Vice President and Chief Financial Officer. Dr. Tung brings 20 years of experience in finance, corporate strategy, and business development in the biopharmaceutical industry. The appointment coincides with the company's reinitiation of the CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes (T1D) treatment.

Prior to joining vTv, Dr. Tung served as CFO of AdvanCell Pty Limited and held senior positions at FibroGen Inc. and Aclaris Therapeutics. He holds B.A. and B.S. degrees in economics and biology from The George Washington University and a combined M.D./M.B.A. from Tufts University School of Medicine.

vTv Therapeutics (VTVT) reported its Q1 2025 financial results and provided updates on its lead drug candidate cadisegliatin. The company has reinitiated screening for its CATT1 Phase 3 trial evaluating cadisegliatin as an adjunctive therapy to insulin for type 1 diabetes treatment. A protocol amendment reduced the trial duration from 12 to 6 months, with topline data expected in 2H 2026. Financially, VTVT reported a cash position of $31.1 million as of March 31, 2025, down from $36.7 million at year-end 2024. The company posted a net loss of $5.1 million ($0.77 per share) compared to $4.9 million ($1.17 per share) in Q1 2024. R&D expenses increased to $2.8 million while G&A expenses decreased to $3.7 million.

vTv Therapeutics has reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class, oral, liver-selective glucokinase activator for Type 1 Diabetes. The company has implemented a protocol amendment that reduces the trial duration from 12 to 6 months, accelerating the timeline to topline data expected in 2H 2026. The study will evaluate approximately 150 patients across 20-25 U.S. sites, with continuous glucose monitors provided to all participants. The trial will assess two doses of cadisegliatin versus placebo, focusing on the primary endpoint of measuring level 2 and level 3 hypoglycemic events. Notably, cadisegliatin has received FDA Breakthrough Therapy designation, positioning it as a promising adjunctive treatment for Type 1 Diabetes.